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Calum E. MacAulay, PhD,* John C. English, MD,† Ming-Sound Tsao, MD,‡ Adi F. Gazdar, MD,§
Stephen Lam, MD,* Wan L. Lam, PhD,* and William W. Lockwood, PhD*
Introduction: Inhibitor of kappa light polypeptide gene enhancer in
B-cells, kinase beta (IKBKB) (IKK-/IKK-2), which activates NF-B,
is a substrate of the KEAP1-CUL3-RBX1 E3-ubiquitin ligase complex,
implicating this complex in NF-B pathway regulation. We investi-
gated complex component gene disruption as a novel genetic mecha-
nism of NF-B activation in non-small cell lung cancer.
Methods: A total of 644 tumor- and 90 cell-line genomes were
analyzed for gene dosage status of the individual complex components
and IKBKB. Gene expression of these genes and NF-B target genes
were analyzed in 48 tumors. IKBKB protein levels were assessed in
tumors with and without complex or IKBKB genetic disruption. Com-
plex component knockdown was performed to assess effects of the
E3-ligase complex on IKBKB and NF-B levels, and phenotypic
importance of IKBKB expression was measured by pharmacological
inhibition.
Results: We observed strikingly frequent genetic disruption (42%)
and aberrant expression (63%) of the E3-ligase complex and IKBKB
in the samples examined. Although both adenocarcinomas and
squamous cell carcinomas showed complex disruption, the patterns
of gene disruption differed. IKBKB levels were elevated with
complex disruption, knockdown of complex components increased
activated forms of IKBKB and NF-B proteins, and IKBKB inhi-
bition detriments cell viability, highlighting the biological signifi-
cance of complex disruption. NF-B target genes were overex-
pressed in samples with complex disruption, further demonstrating
the effect of complex disruption on NF-B activity.
Conclusions: Gene dosage alteration is a prominent mechanism that
disrupts each component of the KEAP1-CUL3-RBX1 complex and
its NF-B stimulating substrate, IKBKB. Herein, we show that,
multiple component disruption of this complex represents a novel
mechanism of NF-B activation in non-small cell lung cancer.
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(J Thorac Oncol. 2011;6: 1521–1529)
KEAP1 is a substrate adaptor protein that binds substratesto an E3-ubiquitin ligase complex, which also includes
CUL3 and RBX1 (Figure 1). Ubiquitination and degradation of
complex substrates prevents their accumulation and undesired
downstream effects. The best characterized substrate of KEAP1
and the E3-complex is NRF2.1–3 In response to oxidative stress,
NRF2 stimulates transcription of cytoprotective genes that scav-
enge harmful reactive molecules, preventing cellular damage.4
Interestingly, lung-specificKEAP1 knockout in mice was shown
to protect against cell damage caused by cigarette smoke by
enabling NRF2 accumulation and increased expression of its
target genes.5 NRF2 has also been implicated in cancer cell
resistance to chemotherapeutics by its activation of drug-metab-
olizing and drug-efflux proteins.4
Recently, the KEAP1 E3-ligase complex has been im-
plicated in the regulation of NF-B signaling,6 which pro-
motes cell proliferation and survival.7–9 The NF-B pathway
is activated in more than 60% of lung cancers; however, the
genetic mechanisms underlying its activation remain largely
unknown.7,10–13 When inactive, NF-B is bound by inhibi-
tory proteins (IB) in the cytoplasm. On stimulation, the
kinase inhibitor of kappa light polypeptide gene enhancer in
B-cells, kinase beta (IKBKB) phosphorylates IB, releasing
its inhibition, and enabling NF-B translocation to the nu-
cleus where it exerts its effects (Figure 1).14 Lee et al.6
demonstrated that KEAP1 binds IKBKB, drawing it to the
E3-ligase complex for ubiquitination and degradation, pro-
viding a mechanism of NF-B regulation. These findings
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provide significant evidence of the integral role of KEAP1
and the E3-ligase complex in NF-B signaling.
The ability of the E3-ligase complex to ubiquitinate
IKBKB was most efficient when all three complex compo-
nents were expressed and intact, suggesting disruption of
even a single component compromises function. Although
somatic DNA alterations have been observed in the genes
encoding some of these complex components, it is not known
whether complex component gene disruptions are a key
mechanism of NF-B activation in lung cancer.6 In lung
cancer, only KEAP1 has been thoroughly investigated at the
DNA level, and a recent study reported that low KEAP1
expression was associated with poor patient outcome.15
KEAP1 deletions, mutations, and DNA hypermethylation
have been reported in 3 to 41% of lung tumors16–21; however,
the moderate frequency of KEAP1 gene disruption alone is
not sufficient to explain the high (60%) frequency of
NF-B activation in lung cancer.11
We propose that genetic disruption of any one E3-
ubiquitin ligase complex component may be sufficient to
result in tumorigenic NF-B activation due to loss of com-
plex function and subsequent accumulation of IKBKB.6,14,22
We hypothesize that somatic disruptions of CUL3 (2q36.2)
and RBX1 (22q13.2), in addition to KEAP1 (19p13.2) occur
frequently in lung tumors, representing a prominent genetic
mechanism that may be responsible for IKBKB accumulation
and stimulation of NF-B. In this study, we (1) investigated
whether these complex components and IKBKB (8p11.21)
exhibit gene dosage and expression alterations and the fre-
quencies at which they occur in a large cohort of clinical lung
tumors, (2) investigated whether the complex components
display subtype-specific disruption, and (3) assessed the func-
tional consequence of complex disruption on NF-B activity,
as these genetic events may be significant contributors to the
NF-B activation commonly observed in lung cancer.
MATERIALS AND METHODS
Non-small Cell Lung Cancer Samples
A total of 261 lung tumors (169 adenocarcinomas
[ACs] and 92 squamous cell carcinomas [SCC]) were accrued
from Vancouver General Hospital (Vancouver, Canada) and
Princess Margaret Hospital (Toronto, Canada) following
ethics approval with patient consent (see Table, Supple-
mental Digital Content 1, which lists patient demograph-
ics, http://links.lww.com/JTO/A112). Tissue sections were
microdissected with the guidance of lung pathologists.
Matched nonmalignant lung tissue was also obtained for a
subset of the primary tumors collected. DNA for all 261
samples was extracted using standard phenol-chloroform pro-
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FIGURE 1. The KEAP1 Cullin-3 E3-ubiquitin ligase complex and its roles in maintaining cellular levels of NRF2 and IKBKB. A,
When complex components are intact, KEAP1 facilitates binding of NRF2 or IKBKB, which promotes their ubiquitination. This
complex prevents accumulation of IKBKB and subsequent NF-B activation. B, Disruption of any complex component com-
promises function leading to stabilization and accumulation of IKBKB and aberrant activation of NF-B.
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cedures. RNA was extracted from tumor and matched non-
malignant tissues using RNeasy Mini Kits (Qiagen Inc.,
Mississauga, ON). Non-small cell lung cancer (NSCLC) cell
lines (H1650, HCC827, H3255, H358, H23, HCC95, H2347,
and H2122) were obtained from American Type Culture
Collection or the laboratory of Adi F. Gazdar and cultivated as
described previously.23 These cell lines were fingerprinted to
confirm their identity.24 Human bronchial epithelial cells
(HBEC-KT) were provided by Dr. John Minna (University of
Texas Southwestern) and maintained as described previously.25
Primary nonmalignant human bronchial epithelial (NHBE) lung
cells were obtained from Lonza (Walkersville, MD).
Determination of Gene Dosage and Expression
Levels
Copy number status (gain, loss, or neutral) for the
KEAP1, CUL3, RBX1, and IKBKB loci was determined for
each tumor sample and 63 NSCLC cell lines by array com-
parative genomic hybridization (CGH) using the whole ge-
nome tiling path array (submegabase resolution tiling
[SMRT] v.2, BCCRC Array Laboratory, Vancouver, BC) as
described previously.26–28 Gene expression levels of KEAP1,
CUL3, RBX1, and IKBKB were determined using custom
Agilent gene expression microarrays in 35 AC and 13 SCC
lung tumors and corresponding matched nonmalignant tis-
sues. Genes were classified as over or underexpressed if the
fold change in messenger RNA (mRNA) expression levels in
tumors relative to matched nonmalignant tissues was greater or
less than twofold. Gene expression for KEAP1, CUL3, RBX1,
and IKBKB was also assessed in an additional, distinct cohort of
49 NSCLC (29 AC and 20 SCC) tumors with matched CGH
profiles using custom Affymetrix arrays. The association be-
tween copy number and gene expression was assessed by seg-
regating these 49 NSCLC tumors into those with and without
copy number alterations for each gene as described previously.28
Expression levels were compared in both groups using a U test
with a p value less than 0.05 considered significant. The probe
with the highest median intensity across all tumor samples was
assessed for each gene.
Copy Number Analysis of External Cohorts
Publically available NSCLC data were investigated to
further explore the frequency of genomic disruption at the
KEAP1, CUL3, RBX1, and IKBKB loci. Affymetrix single
nucleotide polymorphism (SNP) 250K data for 383 matched
tumor nonmalignant NSCLC pairs were accessed from the
dbGaP Genotypes and Phenotypes database (Study Acces-
sion: phs000144.v1.p1). Partek Genomics Suite software was
used to generate copy number profiles for all 383 tumors using
each matched nonmalignant sample as a baseline for defining
copy number alterations. Affymetrix SNP 6.0 array profiles
were obtained for 54 NSCLC cell lines, 27 of which overlapped
with cell lines profiled on the SMRT array, from the Wellcome
Trust Sanger Institute CGP Data Archive (sanger.ac.uk/genetics/
CGP/Archive/) (see Table, Supplemental Digital Content 2,
http://links.lww.com/JTO/A141, which lists NSCLC cell lines
used in this study). Copy number profiles for these cell lines
were also generated using Partek Genomics Suite software using
profiles derived from SNP data for 72 cytogenetically normal
HapMap individuals as a reference.29 In total, 90 unique
NSCLC cell lines were analyzed, and genetic disruption was
noted if either platform (SNP or SMRT array) detected a copy
number alteration. The Broad Institute’s Tumorscape data-
base (www.broadinstitute.org/tumorscape) was also accessed
to investigate copy number status at these four gene loci.30
Western Blot Assessment of Total and
Phospho-IKBKB and Total and Phospho-NF-B
Protein Levels
IKBKB protein levels were assessed in eight NSCLC cell
lines with various combinations of KEAP1, CUL3, or RBX1
genomic loss or IKBKB genomic gain using antibodies from
Cell Signaling (IKBKB no. 2678, p-IKBKB no. 2697, NF-B: no.
4764, p-NF-B: no. 3033, and GAPDH no. 2118, Beverly, MA).
Western blots were performed following standard procedures as
described previously.25 Cells were washed with cold phosphate-
buffered saline and lysed in radioimmunoprecipitation assay
(RIPA) buffer with complete protease inhibitor cocktail (Roche,
Basel, Switzerland). Protein lysates were quantified using the
bicinchoninic acid assay (Fisher Scientific, Ottawa, Canada).
Lysates were diluted and boiled for electrophoresis, then trans-
ferred to a polyvinylidene membrane. Membranes were blocked
in 5% skim milk or 5% BSA in tris-buffered saline containing
Tween 20 (TBS-T) (according to the manufacturer’s recommen-
dations) and then incubated with primary antibody (1:1000) at
4°C overnight. After three washes in TBS-T, membranes were
incubated with HRP-conjugated secondary antibody (Cell Sig-
naling, cat. no. 7074, 1:20000) for 1 hour at room temperature.
Antibody binding was visualized by enhanced chemilumines-
cence (Supersignal West Femto, Thermo Scientific, Rockford,
IL) after three washes in TBS-T.
Immunohistochemistry Staining for IKBKB
Protein Levels
Five-micrometer-thick sections were cut from 13 forma-
lin-fixed paraffin-embedded tumor specimens with various
states of genomic disruption to the E3-ubiquitin ligase complex
genes or IKBKB. Immunohistochemistry to determine protein
expression of IKBKB was performed as described previously.25
Briefly, slides were deparaffinized in xylene and rehydrated with
graded ethanol washes. Antigen retrieval was performed using a
decloaking chamber with sodium citrate buffer pH 6.0, after
which endogenous peroxidase activity was blocked using 3%
H2O2 for 30 minutes at room temperature. Sections were
blocked with goat serum for 3 hours at room temperature and then
incubated overnight at 4°C with 32 g/ml of anti-IKBKB mouse
monoclonal primary antibody (EMD4 Biosciences, cat. OP134,
SanDiego, CA). Before incubationwith an antimouseHRP-strepta-
vidin-conjugated secondary antibody (DAKO, cat. K4000,
Glostrup, Denmark), four 5-minute washes in TBS-T were per-
formed to remove unbound primary antibody. Detection of anti-
body binding was assessed using diaminobenzidine (Sigma Al-
drich, cat. D4293, St. Louis, MO). Slides were counterstained with
hematoxylin for visualization. Intensity of stainingwas scored using
a 0 to 3 systembased on the consensus of three observers (K.L.T.,
L.A.P., and J.C.E.). The mean staining intensity for each tumor
section was judged as follows: 0, no staining; 1, weak intensity; 2,
moderate intensity; and 3, strong staining.
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siRNA-Mediated Complex Component
Knockdowns
On-target plus SMART pool siRNAs targeting KEAP1,
RBX1, CUL3, and a nontargeting control (NTC) pool of small
interfering ribonucleic acid (siRNA) were purchased from Dhar-
macon (Lafayette, CO). One day before transfection, HBEC-KT
cells were plated in regular growth media (antibiotic free) at a
density of 200,000 cells/well in six-well plates. Transfections
were performed using an siRNA concentration of 100 nm
according to the Thermo Scientific DharmaFECT siRNA trans-
fection protocol. DharamaFECT 1 transfection reagent (Dhar-
macon) was used at a concentration of 0.2 l/100 l media.
After 12 hours, transfection media was replaced with regular
growth media. RNA was harvested from cells at 48 hours
posttransfection using the Trizol method (Invitrogen, Carlsbad,
CA) and protein lysates were prepared using RIPA buffer 72
hours posttransfection. Knockdown efficiencies were measured
by quantitative polymerase chain reaction (qPCR) with the follow-
ing TaqMan assays from Applied Biosystems (Carlsbad, CA) and
using 18S as an endogenous control: Hs99999901_s1 (18S),
Hs00202227_m1 (KEAP1), Hs00180183_m1 (CUL3), and
Hs00360274_m1 (RBX1). Western blots were performed as earlier
to measure total and phospho-IKBKB and NF-B protein levels.
NF-B Target Gene Analysis
Nine genes transcriptionally controlled by NF-B - as
annotated in the Ingenuity Pathway Analysis database (Ingenu-
ity Systems, Redwood, CA) were analyzed (see Table, Supple-
mental Digital Content 3, http://links.lww.com/JTO/A142,
which lists the nine NF-B target genes analyzed). Wilcoxon
signed-rank tests were used to compare NF-B target gene
expression in 48 NSCLC tumors with deregulated KEAP1,
CUL3, RBX1, or IKBKB expression levels (twofold or greater)
versus that in their matched nonmalignant lung tissues. NF-B
target genes were considered up-regulated if expression levels
were significantly elevated in tumors relative to matched non-
malignant tissues (Wilcoxon p  0.05).
IKBKB Inhibition in NSCLC Cell Lines
Cell viability assays were performed to measure the effect
of IKBKB inhibition by a cell permeable, competitive ATP
inhibitor, IKK-2 inhibitor IV (Calbiochem cat. #401481, San
Diego, CA) on five NSCLC cell lines (H3255, H2122, H23,
HCC95, and H1650). Cells were plated in triplicate in 96-well
plates at optimal densities for growth (H2122 and H23 at 2000
cells/well, H1650 and HCC95 at 3000 cells/well, and H3255 at
5000 cells/well). Cells were subjected to a series of twofold
dilutions of IKBKB inhibitor, which was prepared in cell growth
media and dimethyl sulfoxide (DMSO). The experimental in-
hibitor concentrations ranged from 500 M to 244 nM, and the
final DMSO concentration for treated and untreated (control)
cells was 1%. Blank wells contained equal volumes of growth
media with 1% DMSO. Cells were incubated for 72 hours at
37°C and then treated with 10 l of Alamar blue cell viability
reagent (Invitrogen) according to manufacturer’s instructions.
The reaction product was quantified by measuring absorbance at
570 nm with reference to 600 nm using an EMax plate reader
(Molecular Devices, Sunnyvale, CA). The average absorbance
readings for blank wells were subtracted from all treatment and
control wells, and technical replicates were averaged. The re-
sponse of treated cells was measured as a proportion of the
viability of untreated cells, with the mean background subtracted
treatment absorbance divided by the mean background sub-
tracted untreated absorbance for each inhibitor concentration.
Dose-response curves and IC50 values were generated in Graph
Pad v5 using the proportionate response of all 12 drug concen-
trations. Experiments were repeated in triplicate and differences
in IC50 values were determined using a Student’s t test with a p
value less than 0.05 considered significant.
RESULTS
Gene Disruption of E3-Ubiquitin Ligase
Complex Components in Multiple NSCLC
Datasets
A total of 261 tumors were screened for DNA copy
number alterations at the KEAP1, CUL3, and RBX1 loci. A
significant proportion of tumor samples (103/261, 39%) showed
genomic loss in at least one of the complex associated genes
(Figure 2A). KEAP1 was the most frequently disrupted complex
component, undergoing genomic loss in 23% of lung tumors
analyzed (Figure 2A). Strikingly, 69% (71/103) of the tumors
harboring copy number alterations had alterations affecting only
one of the genes assessed. Gene expression analysis revealed
aberrant expression in at least one of the complex component
genes in 40% of tumors analyzed (19/48), and of those with
aberrant expression, 84% (16/19) had only one of the genes
affected (Figure 2A). At the expression level, RBX1 was the
most frequently altered complex component, having underex-
pression in 21% of tumors analyzed (Figure 2A). We also
detected a high frequency of IKBKB DNA copy number gain
and mRNA overexpression (23% and 35% of tumors, respec-
tively) (Figure 2A). When IKBKB status was taken into account,
the frequency of NSCLC disruption at any of theKEAP1, CUL3,
RBX1, and/or IKBKB loci rose to 54% (141/261 tumors, Figure
2A) at the gene copy number level and 63% (30/48 tumors,
Figure 2A) at the expression level. Even with the inclusion
of IKBKB, the majority of tumors exhibited complex or
IKBKB genetic disruption at only one gene locus (Figures
2B, C). Frequent genetic disruption of E3-ubiquitin ligase
complex components and IKBKB (73%) was also evident
in NSCLC cell lines (see Table, Supplemental Digital
Content 4, http://links.lww.com/JTO/A143, which describes
complex disruption in NSCLC cell lines).
To determine whether complex component and IKBKB
gene dosage alterations are regulating gene expression, we
integrated DNA copy number and gene expression data for the
complex genes and IKBKB in an additional set of 49 NSCLC
tumors. KEAP1, RBX1, and CUL3, expression was significantly
lower in tumors with genomic loss compared with those without
loss (U test, p  0.00076, p  0.00116, and p  0.00339,
respectively), whereas IKBKB gene expression was ele-
vated in tumors with gain compared with those without (U
test, p  0.0143) (see Figure, Supplemental Digital Content
5, http://links.lww.com/JTO/A113). These findings demonstrate
that dosage alterations affect mRNA expression levels and, there-
fore, likely contribute to E3-ligase complex disruption.
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In addition to the tumor data generated using array
CGH, we analyzed copy number profiles derived from pub-
lically available SNP array data from the dbGaP genotypes
and phenotypes database for an additional 383 pairs of
NSCLCs and matched nonmalignant tissue. Consistent with
our findings, frequent genomic disruption to the E3-ubiquitin
ligase complex components and IKBKB was observed in this
external cohort (see Table, Supplemental Digital Content 4,
http://links.lww.com/JTO/A143, which describes complex dis-
ruption in dbGAP tumors); 34% of the additional 383 tumors
harbored DNA alterations encompassing at least one complex
component or IKBKB. Furthermore, we interrogated the copy
number status of KEAP1, CUL3, RBX1, and IKBKB genes in the
Broad Institute’s Tumorscape database.30 This revealed that
CUL3was significantly deleted in 12% of all 3131 tumors in the
database and in 13% of all NSCLC specimens (n  733), of
which 5.4% had focal CUL3 deletions. Similarly, IKBKB was
significantly amplified in 22% of the all tumors and 28% of
NSCLC specimens, of which 12% contained focal IKBKBDNA
amplifications. KEAP1 and RBX1 were not significantly deleted
in the Tumorscape database.
Differences in Gene Disruption Pattern in
Squamous and AC Subtypes
As distinct patterns of DNA alterations exist for AC
and SCC, we sought to determine whether complex compo-
nent disruption displays subtype-specific patterns of altera-
tion. Although both subtypes of NSCLC showed high fre-
quency of complex component and IKBKB gene disruption,
the pattern of gene disruption differed between these subtypes
(Figure 2D and see Table, Supplemental Digital Content 6,
http://links.lww.com/JTO/A144, which describes complex
disruption in AC and SCC tumors). KEAP1 loss seems to be
the main mechanism of complex disruption in lung AC,
accounting for 64% of the cases that showed disruption (see
Table, Supplemental Digital Content 6) and is more prevalent
in AC than in the SCC subtype (Fisher’s exact test, p 
0.008), in which it is lost in only 16% of cases with compo-
nent disruption (see Table, Supplemental Digital Content 6).
In contrast, CUL3 loss and IKBKB gain occurred more often
in the SCC than AC subtype of lung tumors (Fisher’s exact
test, p  4.926  106 and p  8.446  107, respectively;
see Table, Supplemental Digital Content 6). The increase of
IKBKB gene copy number occurred in 57% of the disrupted
SCC cases and only 26% of disrupted AC cases.
Functional Consequences of Genetic Complex
Disruption
As IKBKB protein levels would be directly affected by
E3-complex function, we assessed IKBKB protein levels in
NSCLC cell lines with and without complex disruption to
measure the consequence of complex disruption. Immuno-
blotting for IKBKB in NHBE cells and a panel of eight
NSCLC cell lines revealed elevated expression levels in lines
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with genomic loss of KEAP1, CUL3, RBX1, or gain of
IKBKB (Figure 3A). To directly assess the effect of complex
component integrity on IKBKB and NF-B activity, we
performed siRNA-mediated knockdowns of KEAP1, CUL3,
and RBX1 in nonmalignant, bronchial epithelial cells. We
achieved at least 80% knockdown for all three genes and
observed an increase in phospho-IKBKB and phospho-
NF-B levels in the knockdowns relative to the NTC, pro-
viding evidence that complex disruption directly regulates
NF-B signaling (Figures 3B, C).
Staining for IKBKB in NSCLC tumors also revealed protein
expression in both complex disrupted and undisrupted tumors
(Supplemental Digital Content 7, http://links.lww.com/JTO/A114);
however, the vast inter- and intratumor heterogeneity in
staining limited our ability to identify any significant corre-
lations between IKBKB protein levels and E3-complex ge-
netic disruption.
To determine whether E3-ligase complex component
underexpression activates NF-B signaling in lung tumors,
expression of nine well-characterized transcriptional targets
of NF-B were analyzed. Of the nine genes, five—BCL2L11,
CXCL13, CXCR4, MMP9, and TRAF1—were significantly
up-regulated in tumors with underexpression of a complex
component or overexpression of IKBKB, when compared
with their matched nonmalignant lung tissue (Figure 4).
Similarly, assessment of the same NF-B target genes fol-
lowing siRNA confirmed these genes to be overexpressed
relative to NTCs (data not shown).
Pharmacological Inhibition of IKBKB
Overexpression of IKBKB can contribute to a malig-
nant phenotype through activation of the NF-B signaling
pathway and consequential effects on cell growth. As such,
we hypothesized that cells dependent on this pathway would
be more sensitive to IKBKB inhibition than those without
complex alterations and normal IKBKB protein levels.
IKBKB inhibition experiments revealed that H1650, an AC
line without genomic loss of any complex component, had
reduced sensitivity to IKBKB inhibition (IC50 13.41) than
H2122 and H23 (IC50 8.19 and 6.59, respectively), which
have multiple components altered (Student’s t test, p  0.05)
(Figure 5). H3255 and HCC95 showed greater insensitivity to
inhibition than H1650 (Student’s t test, p  0.05); however,
these two cell lines have the highest IKBKB protein expres-
sion levels of the cell lines we tested, which likely contrib-
uted to their relative resistance to inhibition. Replicate exper-
iments were highly reproducible, with similar trends in
sensitivity observed across all replicates.
DISCUSSION
The NF-B pathway is aberrantly activated in the
majority of lung cancers and is essential in mouse models of
lung tumorigenesis.10–13 NF-B signaling contributes to tu-
morigenesis by its promotion of cell proliferation and sur-
vival.7–9 For NF-B to become active, inhibition by IB must
be released. This is achieved through phosphorylation of IB
by the kinase, IKBKB14; hence, IKBKB has a critical role in
NF-B activation.6,14 In fact, constitutive IKBKB activity has
been postulated to drive the aberrant NF-B activation ob-
served in cancer.8 Despite what is known about the cascade of
protein signaling events that result in NF-B activation, the
genetic mechanisms responsible for the aberrant activation of
NF-B signaling in lung cancer are not well understood. In
this study, we hypothesized that genetic disruption and loss of
function of the KEAP1 E3-ubiquitin ligase complex, which
regulates IKBKB protein levels, is a major mechanism of
IKBKB accumulation and consequential NF-B activation in
lung cancer.
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FIGURE 3. IKBKB protein expression in non-small cell lung
cancer (NSCLC). A, Western blot depicting IKBKB protein
expression in eight cell lines with varying degrees of genetic
disruption to KEAP1 E3-ligase complex components and/or
IKBKB (as determined from copy number profiles of 90
NSCLC cell lines). Nonmalignant human bronchial epithelial
(NHBE) lung line provides a baseline for IKBKB expression.
The number of disrupted genes for each line is indicated
above the cell line. B, qPCR assessment of mRNA expression
levels for KEAP1, RBX1, and CUL3 after siRNA-mediated
knockdown relative to a nontargeting control (siNTC). Error
bars represent the standard error in relative expression
across all biological replicates. C, Western blot depicting the
effects of transient siRNA knockdown of KEAP1, RBX1, and
CUL3, on total and phospho-IKBKB and NF-B protein levels.
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Our results provide evidence that somatic E3-ligase
complex disruption is a prominent genetic mechanism of
NF-B activation in lung cancer that compromises the ability
of cells to degrade the NF-B activator, IKBKB. We discov-
ered a remarkably high frequency of both genetic disruption
and gene expression changes for the genes encoding E3-
ligase protein components (KEAP1, RBX1, and CUL3) and
the gene encoding the complex’s oncogenic substrate, IK-
BKB. We found that genetic disruption of the complex genes
alters mRNA expression and results in elevated IKBKB
protein levels, demonstrating the consequence of complex
disruption. Moreover, we demonstrated evidence of NF-B
activation in complex compromised lung tumors and showed
the importance of IKBKB protein expression in driving the
lung cancer phenotype.
Although genetic and epigenetic disruption of KEAP1
has been reported in lung cancer before, to our knowledge,
this is the first study to comprehensively characterize somatic
gene dosage alterations to the CUL3, RBX1, and IKBKB loci
in a large cohort of clinical lung tumors. The strikingly high
frequency of copy number and gene expression alterations
observed in our study highlights the importance of these
E3-ubiquitin ligase complex components and also IKBKB in
lung cancer. The recurrent nature of DNA copy number
alterations at the complex component loci and their effects on
gene expression are strong evidence that these genes are
targeted for dosage alterations as opposed to passengers of
alterations targeting other genes. In addition, the high pro-
portion of disrupted lung tumors observed to have genetic
alterations affecting a single component only, at both the
copy number (67%, Figure 2B) and gene expression levels
(73%, Figure 2C), suggests that disruption of only a single
complex component is sufficient to compromise complex
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FIGURE 4. Activation of NF-B targets in
tumors with aberrant expression of KEAP1
E3-ligase complex components and/or IK-
BKB. A–D, Box and whisker plots demon-
strating four examples of NF-B target
genes (BCL2L11, CXCL13, MMP9, and
TRAF1) that are significantly up-regulated
in tumors with underexpression of KEAP1,
RBX1, and/or CUL3 or overexpression of
IKBKB, relative to matched nonmalignant
lung tissues (Wilcoxon sign rank test, p 
0.001). Copy number status of the NF-B
target gene loci was determined in these
tumors to ensure that overexpression was
not due to dosage changes of the target
genes.
Cell Line Copy Number Altera on status IKBKB protein levels IC50  
H1650 No altera ons - 13.4 
H2122 3 components + 8.19 
H23 3 components + 6.59 
H3255 1 component +++ 1.27x10^18 
HCC95 4 components ++ 60.02 
-1 0 1 2 3
0.0
0.5
1.0
1.5
HCC95
H23
H1650
H2122
H3255
Log10 IKBKB inhibitor concentration (µM)
R
es
po
ns
e
(P
ro
po
rt
io
n 
of
 C
on
tr
ol
)
FIGURE 5. Pharmacological inhibition of IKBKB in non-
small cell lung cancer (NSCLC) cells. Alamar blue cell viabil-
ity assays were performed to measure the effect of IKBKB
inhibition by a cell permeable, competitive ATP inhibitor,
IKK-2 inhibitor IV on five NSCLC cell lines. H2122, H23,
H3255, and HCC95 harbored genetic alterations to either
IKBKB or one or more of the KEAP1 E3-ligase complex com-
ponents, whereas H1650 was not altered at the DNA level.
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function and promote NF-B signaling through abnormal
IKBKB accumulation. Interestingly, we observed differential
complex component disruption patterns in AC and SCC
subtypes (Figure 2D). Although E3-ubiquitin ligase complex
disruption occurs in both subtypes, the differences in the
component genes preferentially altered suggests that complex
disruption is achieved by different means.
Examination of IKBKB protein levels in NSCLC cell
lines revealed high expression in lines harboring genetic
disruption to at least one complex component or IKBKB,
whereas the nonmalignant lung line (NHBE) and a line
without genetic disruption (H1650) showed very low or
undetectable levels. The E3-ligase complex was considered
to be genetically intact in H1650, as neither underexpression
of KEAP1, RBX1, and CUL3 nor overexpression of IKBKB
relative to NHBE cells was observed (data not shown). This
suggests that there are no genetic or epigenetic alterations
affecting the complex components or IKBKB in this cell line,
and the observed IKBKB levels were consistent with H1650
having a functioning E3-ligase complex, supporting our hy-
pothesis. Therefore, in addition to affecting gene expression,
copy number losses of the loci coding for complex compo-
nents and gains of IKBKB seem to influence IKBKB protein
expression. A trend toward higher IKBKB expression in lines
with more complex components/IKBKB alterations was not
evident, suggesting that genetic disruption of a single com-
ponent is sufficient to result in loss of complex function and
IKBKB accumulation (Figure 3A). This finding is consistent
with the observation that the majority of tumors exhibiting
complex disruption have only one complex component al-
tered, further supporting the idea that single component
disruption is sufficient to produce an oncogenic effect.
Given our hypothesis, we focused on measuring gene
dosage alterations that could account for disruption of the
E3-ubiquitin ligase complex and its downstream conse-
quences. Nevertheless, it is conceivable that other genetic and
epigenetic mechanisms could also contribute to silencing of
the E3-ubiquitin ligase complex components, thereby con-
tributing to the observed accumulation of IKBKB and aber-
rant NF-B signaling. Mutations and hypermethylation of
KEAP1 have been described, and these events can result in
down-regulation of KEAP1 expression.15,17,18,21 The Cato-
logue of Somatic Mutations in Cancer database has compiled
mutation status for thousands of genes in cancer genomes.31
As KEAP1mutations are known to exist in lung cancer (albeit
at low frequencies), we searched Catologue of Somatic Mu-
tations in Cancer for reported mutations in RBX1, CUL3, and
IKBKB. No RBX1 mutations have been reported in more than
170 cancer samples analyzed, whereas CUL3 and IKBKB
mutations have been identified in 3 of 173 and 5 of 660
cancer samples, respectively, of which only one IKBKB
mutation was in lung cancer. Thus, the rarity of mutations in
these genes in lung cancer specifically suggests that they are
unlikely to be mutated and unlikely to play a role in complex
disruption in the lung cancer cell lines we assessed. Further-
more, we have shown that DNA alterations at the KEAP1,
CUL3, RBX1, and IKBKB loci are associated with concurrent
expression changes, providing evidence that gene dosage
alterations are a significant mechanism driving complex dis-
ruption at the genetic level.
We have conclusively demonstrated elevated IKBKB
protein expression in NSCLC cell lines with complex disrup-
tion; however, measuring this effect directly in tumor tissue
sections was not a straightforward task due to the extent of
heterogeneity in tumor staining intensity across and within
individual tumors. The variation in tissue distribution of
stained cells is exemplified by two tumor samples shown in
Supplemental Digital Content 7B (genetic complex disrup-
tion) and 7C (no genetic complex disruption) and likely
reflects the heterogeneous nature of lung tumor specimens.
Because of this innate tumor heterogeneity, unlike cell
lines, we were unable to conclude whether there was a
significant correlation between E3-ligase complex disrup-
tion and IKBKB protein levels in vivo.
To investigate the direct consequence of complex dis-
ruption on IKBKB accumulation and NF-B activity, we
performed siRNA knockdowns on the individual complex
coding genes (KEAP1, RBX1, and CUL3). Consistent with
our hypothesis, we observed elevated levels of activated
IKBKB and NF-B on complex component disruption in
HBEC cells (Figure 3C). As phospho-NF-B is an indicator
of active NF-B signaling, these results clearly illustrate the
functional consequence of E3-ligase complex disruption. Our
work provides evidence to support the hypothesis that genetic
loss of the complex component encoding genes causes down-
regulation in their expression and that loss of expression of
these genes results in increased levels of activated IKBKB
and NF-B.
A number of reports have detailed the critical role of
IKBKB protein in driving NF-B activation, and the impor-
tance of IKBKB to cancer cell viability is emphasized by the
development of IKBKB inhibitors as a strategy for tempering
NF-B signaling.8,14,22 We found that IKBKB inhibition
reduced NSCLC cell viability and that cells without complex
or IKBKB disruption, which we hypothesized to be less
dependent on IKBKB expression for growth, were indeed
more insensitive to IKBKB inhibition, as were cells with high
endogenous levels of IKBKB protein (Figure 5). In addition
to cell experiments to verify the importance of E3-ligase
complex disruption in lung cancer, we analyzed the expres-
sion levels of several NF-B target genes in tumors with
complex disruption to measure its effect on NF-B activity.
Despite the possibility that other mechanisms could also
contribute to the transcription of the NF-B target genes, we
observed a significant increase in the expression of NF-B
target genes in complex compromised tumors (Figure 4). We
also observed elevated expression of NF-B target genes
after knockdown of the E3-ligase complex components. To-
gether, these findings support our hypotheses and demon-
strate the biological significance of complex disruption and
subsequent IKBKB overexpression in lung cancer biology.
Collectively, our analyses have revealed remarkably
frequent genetic disruption and aberrant expression not only
of KEAP1 but also all members of the KEAP1 E3-ubiquitin
ligase complex and IKBKB in lung cancer. We have shown
that IKBKB protein expression is elevated in NSCLCs with
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genetic loss of KEAP1, CUL3, or RBX1 or gain of IKBKB and
that knockdown of complex components leads to an accumu-
lation of active IKBKB and NF-B, thereby demonstrating
the functional consequence and significance of complex dis-
ruption. We have also provided evidence of NF-B activity,
a downstream effect of IKBKB accumulation, in complex
disrupted tumors and cell lines. Interestingly, it seems that
AC and SCCs of the lung acquire copy number alterations to
different components of the E3-complex or IKBKB, which
suggests the genetic mechanisms of complex disruption that
promote NF-B activation may be subtype specific. Our
findings suggest that prominent genetic disruption to the
E3-ubiquitin ligase complex and its oncogenic substrate,
IKBKB, play a major role in driving the aberrant NF-B
activation that is characteristic of lung tumorigenesis.
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